EBS · Emergent BioSolutions Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-01 | Williams Paul Anthony |
SVP, Products Business |
Sell↓
Filing footnotes — Common Stock (Direct)
All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.31 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
3,000 |
| 2026-06-08 | Hartzel William |
SVP, Bioservices |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |
Common Stock
|
1,741 |
| 2026-06-08 | Glessner Coleen |
EVP, Quality & Ethics, and CPL |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. |
Common Stock
|
2,018 |
| 2026-06-08 | LINDAHL RICHARD S |
EVP, Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. |
Common Stock
|
3,964 |
| 2026-06-08 | Williams Paul Anthony |
SVP, Products Business |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units. |
Common Stock
|
694 |
| 2026-05-01 | Dayal Sujata Tyagi |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 8, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.70 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
980 |
| 2026-05-01 | Dayal Sujata Tyagi |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 8, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.70 to $8.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
12,781 |
| 2026-05-01 | Zoon Kathryn C |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
16,145 |
| 2026-05-01 | DeGolyer Donald W |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.78 to $8.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
14,527 |
| 2026-05-01 | DeGolyer Donald W |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated August 11, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.80 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
954 |
| 2026-05-01 | Zoon Kathryn C |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.79 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
1,057 |
| 2026-04-30 | Katkin Keith |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-30 | Katkin Keith |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 10, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026. The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.23 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
15,481 |
| 2026-04-30 | Fowler Neal Franklin |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-30 | White Marvin L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-30 | Richard Ronald |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Option (Right to Buy)
|
11,296 |
| 2026-04-30 | FOWLER JOHN D JR |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-30 | Katkin Keith |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Options (Right to Buy)
|
11,296 |
| 2026-04-30 | Harsanyi Zsolt |
Director, Chairman |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-30 | FOWLER JOHN D JR |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Option (Right to Buy)
|
11,296 |
| 2026-04-30 | DeGolyer Donald W |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-30 | Richard Ronald |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-30 | Zoon Kathryn C |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Option (Right to Buy)
|
11,296 |
| 2026-04-30 | Fowler Neal Franklin |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Option (Right to Buy)
|
11,296 |
| 2026-04-30 | Dayal Sujata Tyagi |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-30 | Dayal Sujata Tyagi |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Option (Right to Buy)
|
11,296 |
| 2026-04-30 | DeGolyer Donald W |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Option (Right to Buy)
|
11,296 |
| 2026-04-30 | Harsanyi Zsolt |
Director, Chairman |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Option (Right to Buy)
|
11,296 |
| 2026-04-30 | White Marvin L |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Stock Option (Right to Buy)
|
11,296 |
| 2026-04-30 | Zoon Kathryn C |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
Common Stock
|
25,344 |
| 2026-04-29 | Williams Paul Anthony |
SVP, Products Business |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Common Stock
|
100,111 |
| 2026-04-29 | Perl Jessica |
SVP, General Counsel, Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Common Stock
|
104,282 |
| 2026-04-29 | Glessner Coleen |
EVP, Quality & Ethics, and CPL |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Common Stock
|
100,111 |
| 2026-04-29 | Hartzel William |
SVP, Bioservices |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Common Stock
|
100,111 |
| 2026-04-29 | LINDAHL RICHARD S |
EVP, Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Common Stock
|
162,680 |
| 2026-04-29 | PAPA JOSEPH C |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Common Stock
|
187,708 |
| 2026-04-29 | Lowry Simon C |
SVP, R&D, CMO |
Award↑
Filing footnotes — Common Stock (Direct)
The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Common Stock
|
100,111 |
| 2026-04-01 | Williams Paul Anthony |
SVP, Products Business |
Sell↓
Filing footnotes — Common Stock (Direct)
All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 14, 2025 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Common Stock
|
4,000 |
| 2026-03-05 | Lowry Simon C |
SVP, R&D, CMO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |
Common Stock
|
10,636 |
| 2026-03-05 | Perl Jessica |
SVP, General Counsel, Corp Sec |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |
Common Stock
|
6,465 |
| 2026-03-05 | PAPA JOSEPH C |
Director, President and CEO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of performance stock units. |
Common Stock
|
37,055 |
| 2026-03-05 | LINDAHL RICHARD S |
EVP, Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |
Common Stock
|
23,650 |
| 2026-03-05 | Hartzel William |
SVP, Bioservices |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |
Common Stock
|
9,493 |
| 2026-03-05 | Williams Paul Anthony |
SVP, Products Business |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |
Common Stock
|
9,397 |
| 2026-03-05 | Glessner Coleen |
EVP, Quality & Ethics, and CPL |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |
Common Stock
|
8,199 |
| 2026-03-03 | Glessner Coleen |
EVP, Quality & Ethics, and CPL |
Award↑
Filing footnotes — Employee Stock Option (Right to buy) (Direct)
Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |
Employee Stock Option (Right to buy)
|
44,834 |
| 2026-03-03 | Lowry Simon C |
SVP, R&D, CMO |
Award↑
Filing footnotes — Employee Stock Option (Right to buy) (Direct)
Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |
Employee Stock Option (Right to buy)
|
44,834 |
| 2026-03-03 | Hartzel William |
SVP, Bioservices |
Award↑
Filing footnotes — Employee Stock Option (Right to buy) (Direct)
Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |
Employee Stock Option (Right to buy)
|
44,834 |
| 2026-03-03 | Williams Paul Anthony |
SVP, Products Business |
Award↑
Filing footnotes — Employee Stock Option (Right to buy) (Direct)
Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |
Employee Stock Option (Right to buy)
|
44,834 |
| 2026-03-03 | FOWLER JOHN D JR |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. |
Common Stock
|
5,006 |